Skip to contentpdufa.bio

obexelimab Phase

Page updated ·next FDA decision on the calendar ·Data as of Nov 19, 2026 12:24 AM ET

obexelimab Phase is a Zenas BioPharma, Inc. program in systemic lupus erythematosus. Its next catalyst is a Readout in Q4 2026.

ZBIO catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

Indication under review: Systemic lupus erythematosus. Sponsor: Zenas BioPharma, Inc. (ZBIO). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

Readout · Q4 2026ZBIO

Specialist biotech funds holding ZBIO, 13F for the quarter ended September 30, 2026

FundSharesValue at quarter endFiling
EcoR1 Capital789,500$21.3 millionfiled November 16, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is obexelimab Phase's next FDA decision or readout?

The next tracked catalyst for obexelimab Phase is a Readout in Q4 2026.

What happened at obexelimab Phase's most recent FDA decision?

No FDA decision for obexelimab Phase is in our archive yet.

What is obexelimab Phase used for?

In our records obexelimab Phase is under review or in development for Systemic lupus erythematosus.

Who makes obexelimab Phase?

Zenas BioPharma, Inc. (ZBIO).

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.